Epigenetic Reprogramming Enters First Human Trial for Longevity, While Cloning Limits and AI Advances Reshape Science

This category focuses on scientific and technological advancements, which generally carry a low immediate risk of conflict or instability. The developments are primarily in research and medical fields, with long-term societal implications rather than immediate geopolitical risks.

📌 Key developments

• Longevity Research Enters First Human Trial with Epigenetic Reprogramming Life Biosciences has received approval from US regulators (the Food and Drug Administration, or FDA) to begin human trials for ER-100, an epigenetic reprogramming therapy, specifically for optic neuropathies, which are diseases affecting the optic nerve. This therapy uses three of the four "Yamanaka factors" (Oct4, Sox2, and Klf4), which are special proteins that can reset cells to a more youthful state, delivered directly to the eye. This is the first time a cellular reprogramming technology, aimed at reversing age-related cellular changes, is being tested in humans, offering a potential new way to fight aging and age-related diseases, including those that cause vision loss, a condition that can be particularly feared among many, including Iranian readers. This is a very early-stage human trial, meaning it will be many years before it could potentially become a widely available treatment. Researchers deliberately excluded the fourth Yamanaka factor, c-Myc, because it is linked to tumor formation. It does not yet prove that epigenetic reprogramming can safely or effectively reverse aging or cure optic neuropathies in humans, nor does it mean it will extend overall human lifespan.
• Long-Term Study Reveals Genetic Limits of Mammalian Cloning A two-decade-long study in Japan, published in Nature Communications, involving the repeated cloning of mice for 58 generations, has definitively shown that serial cloning in mammals eventually leads to a fatal accumulation of genetic mutations. While early generations appeared healthy, mutations began to pile up after about 25 generations, becoming lethal by the 58th generation, which died shortly after birth. This research contradicts the previous belief that cloning could be carried out indefinitely and highlights the critical role of sexual reproduction in mammals for maintaining genetic health and eliminating harmful mutations. These findings improve our understanding of mammalian genetics and the technological limits of cloning, reinforcing that, unlike some plants or lower animals, mammals cannot sustain their species through cloning alone. It does not mean that all cloning attempts are doomed to fail, especially for a limited number of generations, but it strongly suggests that long-term, serial cloning of mammals is not biologically sustainable.
• AI Breakthrough: NASA and IBM Launch Open-Source Lunar Foundation Model IBM and NASA have collaboratively released the NASA-IBM Lunar Foundation Model, which is one of the first open-source artificial intelligence (AI) foundation models specifically designed for lunar science. This AI model processes decades of vast lunar observation data from multiple missions, including images and geophysical data, to provide a unified framework for researchers worldwide. This breakthrough is reshaping planetary exploration by making complex lunar datasets more accessible and analyzable, allowing researchers to uncover structural patterns across lunar terrain that individual instruments might miss, significantly accelerating lunar exploration and supporting future human missions to the Moon. This open-source model will empower a global community of scientists to conduct more efficient and precise lunar research, and is expected to lead to new discoveries about the Moon's geology and help prepare for sustained human presence there. While it accelerates analysis, it does not independently make new physical discoveries; it is a tool that enhances human scientific capability.
• New Real-World Data Improves Schizophrenia Treatment Strategies Teva Pharmaceuticals presented new real-world data at Psych Congress (September 15-19, 2026) showing that UZEDY (risperidone extended-release injectable suspension), a long-acting injectable antipsychotic, helps adults with schizophrenia stay on treatment longer and significantly reduces emergency room visits and hospitalizations. Additionally, post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous injectable olanzapine, highlighted high rates of stabilization and long-term efficacy for schizophrenia. Schizophrenia is a severe mental illness that often requires continuous treatment, and treatment adherence can be a major challenge, leading to psychiatric emergencies. These findings indicate that long-acting injectable medications like UZEDY and the pipeline drug TEV-'749 can improve patient stability, reduce the burden on healthcare systems, and lower costs, offering better quality of life for patients and their families. UZEDY is already available, and these data reinforce its benefits in routine care. TEV-'749 is awaiting an anticipated FDA approval decision in Q4, which could provide another important once-monthly option for patients. While the data is promising for treatment continuity and reducing acute care, it does not suggest a cure for schizophrenia, nor does it eliminate the need for comprehensive mental health support.
• Hair Loss Treatments Advance with Stem Cell and Topical Approaches The field of hair loss treatment is seeing significant advancements. Pelage Pharmaceuticals' topical treatment, PP405, which targets hair follicle stem cells to reactivate dormant follicles, showed promising results in Phase II trials with 31% of men achieving over 20% increased hair density, and Phase III studies are planned for 2026. Separately, clascoterone, a topical androgen receptor inhibitor, is emerging as a significant breakthrough, particularly for women with androgenetic alopecia (pattern hair loss), as it acts locally without systemic hormonal exposure. Hair loss, or androgenetic alopecia, is a widely known and often feared condition among many, including Iranian readers. These innovations offer non-surgical, regenerative approaches and targeted treatments that could improve hair density and quality, especially for populations with limited options. PP405 is still in clinical trials and years away from potential availability. Clascoterone's Phase 3 results are significant, and if approved, it would fill a crucial gap for women's hair loss treatment. These treatments are not miracle cures for complete baldness and are still in various stages of development or approval. Their long-term efficacy and safety profiles are still being fully established.
• Supplements Face Increased Scrutiny and Verification Demands In 2026, the US Food and Drug Administration (FDA) has issued multiple warning letters and safety alerts for dietary supplements making illegal disease claims, containing undeclared stimulants or steroids, or having inaccurate ingredient levels (e.g., melatonin, omega-3s, magnesium). This highlights a significant issue with product quality and misleading marketing in the supplement industry. Many people, including Iranian readers, turn to supplements for health concerns like aging, hair loss, or general wellness. However, the lack of robust regulation means consumers often cannot trust label claims. This scrutiny emphasizes the importance of choosing supplements that have undergone independent "third-party testing" by organizations like NSF International or USP (United States Pharmacopeia), which verify ingredients, potency, purity, and absence of contaminants. While some supplements, like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have shown strong evidence in human trials for doubling NAD+ levels (a molecule important for cell energy), many others lack such rigorous proof. Strong evidence for a supplement's effect does not automatically translate to proven health benefits or disease prevention in humans, and individual results can vary. The warnings do not mean all supplements are ineffective or dangerous, but rather that consumers must be highly discerning.

💡 Why it matters

These advancements are crucial for understanding the future of human health, extending healthy lifespans, and expanding our capabilities in space exploration. For policymakers, the progress in AI and genetics raises questions about ethical guidelines and long-term societal impacts, while medical and supplement developments underscore the importance of robust regulatory frameworks and evidence-based public health information.

🎭 People in the news

• Dr. Teruhiko Wakayama — Developmental biologist at the University of Yamanashi, senior author of the 20-year study on the limits of mammalian cloning.
• Dr. Eric Hughes — Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceuticals, who presented new real-world data on schizophrenia treatments.
• King Charles III — Met with senior leaders from major AI companies to discuss controlling AI and ensuring it benefits society.

👀 What to watch

• Further updates on the epigenetic reprogramming human trials, including initial safety and efficacy data.
• Developments in AI applications for scientific research and the ongoing discussions about AI safety and regulation, such as those initiated by King Charles III.
• The FDA's anticipated approval decision for Teva's TEV-'749 for schizophrenia in Q4 2026, which could impact treatment options for mental health.
• Continued research into hair loss treatments, particularly the progression of PP405 into Phase III trials and the broader availability of clascoterone.